talkmarkets Dr. Patterson was asked to handicap t
Post# of 155271
(Total Views: 1015)
Posted On: 08/03/2020 9:23:19 PM
talkmarkets Dr. Patterson was asked to handicap the DSMC meeting.
“I do think it's a better metric than having a clinical score. There was a lot of confusion when Nader mentioned there were a lot of deaths, but what he was actually trying to say was you need a number of deaths to be able to achieve statistical significance. . . . If you have 60 deaths and you have only 20 deaths in the treated group and 40 deaths in the placebo group you've got the numbers on your side to say that is statistically significant. That's what he was trying to say. Not that you have a lot of deaths. ”
What this means is that in the next couple of days it's possible for the DSMC to compare the number of deaths in the active versus placebo arm and make a recommendation to the FDA that the placebo arm be given the active drug and that CytoDyn should be allowed to conduct an interim readout with the purpose of approving the drug. In the past catalysts like this have been extremely rare, but have led to exponential increases in stock price. In 2014 the DSMB recommended the stoppage of Intercept Pharmaceuticals (Nasdaq: ICPT) mid-stage Flint trial for meeting their endpoint. The stock rocketed 280% and then another 50% a day later on the news
“I do think it's a better metric than having a clinical score. There was a lot of confusion when Nader mentioned there were a lot of deaths, but what he was actually trying to say was you need a number of deaths to be able to achieve statistical significance. . . . If you have 60 deaths and you have only 20 deaths in the treated group and 40 deaths in the placebo group you've got the numbers on your side to say that is statistically significant. That's what he was trying to say. Not that you have a lot of deaths. ”
What this means is that in the next couple of days it's possible for the DSMC to compare the number of deaths in the active versus placebo arm and make a recommendation to the FDA that the placebo arm be given the active drug and that CytoDyn should be allowed to conduct an interim readout with the purpose of approving the drug. In the past catalysts like this have been extremely rare, but have led to exponential increases in stock price. In 2014 the DSMB recommended the stoppage of Intercept Pharmaceuticals (Nasdaq: ICPT) mid-stage Flint trial for meeting their endpoint. The stock rocketed 280% and then another 50% a day later on the news
(4)
(0)